Massachusetts, November 17, 2026
ProMIS Neurosciences Inc. (NASDAQ: PMN) has entered into a licensing agreement with Ossianix, Inc. to access its next-generation TXP1 brain-selective shuttling technology, designed to improve the delivery of therapeutic antibodies across the blood-brain barrier. The agreement aims to expand ProMIS’s lead Alzheimer’s disease drug candidate, PMN310, and strengthen its development pipeline targeting other neurodegenerative disorders, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The collaboration represents an important development in biopharmaceutical innovation and targeted drug delivery, addressing one of the major challenges in developing antibody-based treatments for neurological conditions.
TXP1 Technology Demonstrates Enhanced Brain Delivery
The licensed TXP1 technology targets transferrin receptor 1 (TfR1), a receptor involved in transporting molecules across the blood-brain barrier. The technology is built on a deimmunized, single-domain VNAR antibody scaffold, which is significantly smaller than conventional antibodies and is designed to facilitate selective delivery into brain tissue. According to preclinical studies reported by Ossianix, including studies conducted in non-human primates, TXP1 increased the delivery of a therapeutic antibody to the brain by more than 65-fold. The company also reported prolonged brain exposure, a favorable pharmacokinetic profile and no observed accumulation in several peripheral organs, including the liver, spleen, lungs, kidneys, bone marrow, heart and muscles. Additionally, the technology demonstrated binding that does not compete with transferrin and minimal impact on reticulocyte levels, addressing potential considerations associated with some TfR1-targeting approaches. These findings highlight the potential of TXP1 as a next-generation platform for improving the delivery of biologic medicines to the central nervous system.
Licensing Agreement Expands PMN310 and Neurodegenerative Pipeline
Under the licensing agreement, ProMIS Neurosciences receives rights to use TXP1 with PMN310, its lead investigational antibody candidate for Alzheimer’s disease. The agreement also provides options to extend the technology to PMN442, which targets alpha-synuclein associated with Parkinson’s disease and dementia with Lewy bodies, and PMN267, an antibody targeting TDP-43 associated with ALS and frontotemporal dementia. The collaboration is intended to support the development of potential next-generation therapeutic candidates with improved brain delivery characteristics. ProMIS believes that combining its antibodies, which selectively target toxic misfolded protein oligomers, with TXP1 could support a second-generation PMN310 with a potentially more convenient subcutaneous dosing schedule and lower manufacturing costs. Under the financial terms, Ossianix will receive an upfront payment and may qualify for additional development, regulatory and commercial milestone payments, along with royalties on global net sales. ProMIS expects to fund its near-term obligations using existing cash resources and has stated that the agreement is not expected to change its previously disclosed cash runway through 2027.
PMN310 Clinical Development and Future Opportunities
PMN310 is a humanized IgG1 monoclonal antibody developed to selectively target toxic amyloid-beta oligomers associated with Alzheimer’s disease while avoiding amyloid plaques. This approach is intended to address toxic protein species while potentially reducing or eliminating the risk of amyloid-related imaging abnormalities (ARIA) associated with certain amyloid-targeting therapies. PMN310 received Fast Track designation from the U.S. Food and Drug Administration (FDA) in July 2025 and is currently being evaluated in the PRECISE-AD Phase 1b clinical study. The randomized, double-blind, placebo-controlled study is investigating the candidate in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease. The TXP1 licensing agreement does not replace or alter the ongoing development of the existing PMN310 candidate. Instead, it provides ProMIS with an additional technology option for developing potential next-generation formulations and expanding its therapeutic pipeline. Any anticipated improvements in dosing, brain exposure or manufacturing costs will require further evaluation and clinical validation.
Source: ProMIS Neurosciences press release



